IBRX
Neutral signalScored 2026-10-11 Drivers: trend, fundamentals. Insiders: neutral. Moteurs : tendance, fondamentaux. Initiés : neutre.
Research, not advice.
À propos
ImmunityBio, Inc.
- Nom
- ImmunityBio, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $8.8B
- Employés
- 688
- PDG
- Richard Gerald Adcock
- Site web
- https://immunitybio.com
- Marché
- ALLOATRABNTXIMCRIMTXIOVA
ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell) immune system. ImmunityBio currently has several therapeutic candidates in advanced clinical development, with agents undergoing Phase II or III trials. These investigational treatments are aimed at various liquid and solid tumors, such as bladder, pancreatic, and lung cancers, as well as significant infectious pathogens including SARS-CoV-2 and HIV. The company actively engages in strategic partnerships, holding collaboration agreements with esteemed organizations like the National Cancer Institute, the National Institute of Deafness and Communication Disorders, and Amyris, Inc. Additionally, ImmunityBio has secured licensing agreements with numerous entities, including CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 106 056 titres (~1 119 848,00 $ US)
- Insiders
- Simon Barry J.Cohen Cheryl
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$1,119,848
Avg sell (VWAP, 90d window) $10.56 vs last close $9.91 (-6.1%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$1,119,848 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-10-05
- Liquidity
- Liquid $156,797,418/day · 20d vol
- Last synced
-
2026-10-14 21:10:34
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-05 | Simon Barry J. | Sell · S · 10b5-1 | 25,000 | $10.75 | $268,760 | Form 4 |
| 2026-10-02 | Cohen Cheryl | Sell · S · 10b5-1 | 81,056 | $10.50 | $851,088 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
| Date | Member | Side | Amount range | Filing |
|---|---|---|---|---|
| 2026-09-30 | Lisa C. McClain | Buy | $1,001 - $15,000 | Filing |
| 2026-09-28 | Lisa C. McClain | Buy | $1,001 - $15,000 | Filing |
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2023-03-06 | Daniel Goldman | Sale (Full) | $1,001 - $15,000 |
Signal
Neutral signalScored 2026-10-11 Drivers: trend, fundamentals. Insiders: neutral. Moteurs : tendance, fondamentaux. Initiés : neutre.
IBRX combines severe financial distress (persistent negative margins, negative ROIC/ROE, heavy cash burn) with a weak catalyst profile (no identifiable M&A, earnings, or legislative trigger), yielding a low composite…
The first sentence of the analysis written for IBRX on 2026-10-11 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. – Insider: neutral. All sales (≈ $1.1M) were pre-planned Rule 10b5-1 trades, excluded from the score. No open-market buys or discretionary sales. – Initiés : neutre. Toutes les ventes (≈ $1.1M) sont sous plan 10b5-1 préétabli, exclues du score. Aucun achat ni vente discrétionnaire.
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Supports a bullish reading. Interesting trend — weekly bias up
- Financial indicators Unavailable or mixed. Current ratio 5.10 · operating margin -226% — readings disagree
Suggested stop 7.69, nearest stored support minus 0.5 ATR(22.4% under the last close). Reward/risk to the next stored resistance is 0.41. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 99.3% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Ebit Margin | -211.0% | -1912.4% | -79931.7% | -154225.4% | -35866.2% | |
| Ebitda Margin | -197.3% | -1793.4% | -76955.5% | -146617.1% | -34341.8% | |
| Operating Profit Margin | -226.0% | -2334.2% | -58239.5% | -146374.2% | -35361.9% | |
| Pretax Profit Margin | -310.4% | -2805.3% | -93873.3% | -173869.2% | -37456.0% | |
| Continuous Operations Profit Margin | -310.2% | -2805.3% | -93866.9% | -173883.3% | -37457.0% | |
| Net Profit Margin | -310.2% | -2804.8% | -93761.4% | -173569.6% | -37129.6% | |
| Bottom Line Profit Margin | -310.2% | -2804.8% | -93761.4% | -173569.6% | -37129.6% | |
| Current Ratio | 5.099 | 3.360 | 5.046 | 0.281 | 0.906 | |
| Quick Ratio | 5.084 | 3.209 | 5.046 | 0.281 | 0.906 | |
| Solvency Ratio | -0.335 | -0.455 | -0.518 | -0.490 | -0.467 | |
| Cash Ratio | 1.430 | 2.610 | 4.555 | 0.209 | 0.491 | |
| Price To Earnings Ratio | -5.211 | -4.339 | -4.365 | -4.875 | -6.831 | |
| Price To Earnings Growth Ratio | 0.146 | 0.089 | -0.413 | -0.289 | -0.134 | |
| Forward Price To Earnings Growth Ratio | 0.146 | 0.089 | -0.413 | -0.289 | -0.134 | |
| Price To Earnings Diluted Ratio | -5.211 | -4.129 | -4.365 | -4.875 | -6.831 | |
| Price To Earnings Diluted Growth Ratio | 0.135 | 0.090 | -0.413 | -0.289 | -0.134 | |
| Price To Book Ratio | -3.646 | -3.650 | -4.350 | -4.532 | -9.772 | |
| Price To Sales Ratio | 16.077 | 121.066 | 4,105.069 | 8,447.888 | 2,533.773 | |
| Price To Free Cash Flow Ratio | -5.898 | -4.484 | -6.426 | -4.878 | -7.684 | |
| Price To Operating Cash Flow Ratio | -5.973 | -4.563 | -6.962 | -6.007 | -8.624 | |
| Debt To Assets Ratio | 1.750 | 1.317 | 1.441 | 1.997 | 1.377 | |
| Debt To Equity Ratio | -1.758 | -1.031 | -1.238 | -1.618 | -2.666 | |
| Debt To Capital Ratio | 2.320 | 33.459 | 5.201 | 2.618 | 1.600 | |
| Long Term Debt To Capital Ratio | 2.489 | -16.968 | 7.208 | -1.171 | 4.774 | |
| Financial Leverage Ratio | -1.005 | -0.783 | -0.859 | -0.810 | -1.936 | |
| Working Capital Turnover Ratio | 0.592 | 0.081 | -0.010 | -0.001 | 0.209 | |
| Operating Cash Flow Ratio | -4.938 | -7.121 | -6.293 | -0.674 | -0.744 | |
| Operating Cash Flow Sales Ratio | -2.692 | -26.533 | -589.641 | -1,406.287 | -293.810 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.013 | 1.018 | 1.083 | 1.232 | 1.122 | |
| Debt Service Coverage Ratio | -1.834 | -2.008 | -5.519 | -0.735 | -1.021 | |
| Interest Coverage Ratio | -2.275 | -2.614 | -4.177 | -7.451 | -22.243 | |
| Short Term Operating Cash Flow Coverage Ratio | -32.838 | 0.000 | 0.000 | -0.781 | -0.917 | |
| Operating Cash Flow Coverage Ratio | -0.347 | -0.776 | -0.505 | -0.466 | -0.425 | |
| Capital Expenditure Coverage Ratio | -79.287 | -56.800 | -11.992 | -4.318 | -8.176 | |
| Dividend Paid And Capex Coverage Ratio | -79.287 | -56.800 | -11.992 | -4.318 | -8.176 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -11.680 | -8.115 | -6.298 | -7.521 | -8.826 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 99.3% | ▼-0.7% | ▼-0.5% |
| Ebit Margin | -211.0% | ▲1701.4% | ▲54218.3% |
| Ebitda Margin | -197.3% | ▲1596.0% | ▲51783.7% |
| Operating Profit Margin | -226.0% | ▲2108.2% | ▲48281.2% |
| Pretax Profit Margin | -310.4% | ▲2495.0% | ▲61352.5% |
| Continuous Operations Profit Margin | -310.2% | ▲2495.1% | ▲61354.3% |
| Net Profit Margin | -310.2% | ▲2494.6% | ▲61204.9% |
| Bottom Line Profit Margin | -310.2% | ▲2494.6% | ▲61204.9% |
| Current Ratio | 5.099 | ▲1.739 | ▲2.161 |
| Quick Ratio | 5.084 | ▲1.875 | ▲2.179 |
| Solvency Ratio | -0.335 | ▲0.119 | ▲0.118 |
| Cash Ratio | 1.430 | ▼-1.180 | ▼-0.429 |
| Price To Earnings Ratio | -5.210 | ▼-0.872 | ▼-0.086 |
| Price To Earnings Growth Ratio | 0.146 | ▲0.057 | ▲0.267 |
| Forward Price To Earnings Growth Ratio | 0.146 | ▲0.057 | ▲0.267 |
| Price To Earnings Diluted Ratio | -5.210 | ▼-1.081 | ▼-0.128 |
| Price To Earnings Diluted Growth Ratio | 0.135 | ▲0.045 | ▲0.257 |
| Price To Book Ratio | -3.646 | ▲0.004 | ▲1.544 |
| Price To Sales Ratio | 16.077 | ▼-104.989 | ▼-3028.697 |
| Price To Free Cash Flow Ratio | -5.898 | ▼-1.415 | ▼-0.024 |
| Price To Operating Cash Flow Ratio | -5.973 | ▼-1.410 | ▲0.453 |
| Debt To Assets Ratio | 1.750 | ▲0.433 | ▲0.173 |
| Debt To Equity Ratio | -1.758 | ▼-0.727 | ▼-0.096 |
| Debt To Capital Ratio | 2.320 | ▼-31.140 | ▼-6.720 |
| Long Term Debt To Capital Ratio | 2.489 | ▲19.456 | ▲3.222 |
| Financial Leverage Ratio | -1.005 | ▼-0.222 | ▲0.074 |
| Working Capital Turnover Ratio | 0.592 | ▲0.511 | ▲0.418 |
| Operating Cash Flow Ratio | -4.938 | ▲2.183 | ▼-0.984 |
| Operating Cash Flow Sales Ratio | -2.692 | ▲23.842 | ▲461.101 |
| Free Cash Flow Operating Cash Flow Ratio | 1.013 | ▼-0.005 | ▼-0.081 |
| Debt Service Coverage Ratio | -1.834 | ▲0.174 | ▲0.389 |
| Interest Coverage Ratio | -2.275 | ▲0.339 | ▲5.477 |
| Short Term Operating Cash Flow Coverage Ratio | -32.838 | ▼-32.838 | ▼-25.931 |
| Operating Cash Flow Coverage Ratio | -0.347 | ▲0.429 | ▲0.157 |
| Capital Expenditure Coverage Ratio | -79.287 | ▼-22.487 | ▼-47.172 |
| Dividend Paid And Capex Coverage Ratio | -79.287 | ▼-22.487 | ▼-47.172 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -11.680 | ▼-3.565 | ▼-3.192 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $1.82B | $1.79B | $2.55B | $2.03B | $2.37B | |
| Enterprise value | $2.61B | $2.15B | $3.01B | $2.65B | $2.83B | |
| EV / Sales | 23.05x | 145.53x | 4846.66x | 11027.60x | 3031.16x | |
| EV / Op. cash flow | -8.56x | -5.49x | -8.22x | -7.84x | -10.32x | |
| EV / Free cash flow | -8.46x | -5.39x | -7.59x | -6.37x | -9.19x | |
| EV / EBITDA | -11.68x | -8.12x | -6.30x | -7.52x | -8.83x | |
| Net debt / EBITDA | -3.53x | -1.36x | -0.96x | -1.76x | -1.45x | |
| Current ratio | 5.10x | 3.36x | 5.05x | 0.28x | 0.91x | |
| Income quality | 0.87x | 0.95x | 0.63x | 0.81x | 0.79x | |
| Graham net-net | -$1 | -$1 | -$2 | -$2 | -$1 | |
| Tax burden | 99.9% | 100.0% | 99.9% | 99.8% | 99.1% | |
| Interest burden | 147.1% | 146.7% | 117.4% | 112.7% | 104.4% | |
| Working capital | $253.1M | $129.6M | $235.8M | -$360.3M | -$34.6M | |
| Invested capital | $414.6M | $316.0M | $435.6M | -$150.8M | $85.9M | |
| Return on assets | -70.0% | -108.0% | -115.6% | -115.0% | -74.0% | |
| Operating ROA | -57.9% | -77.6% | -83.6% | -84.5% | -95.7% | |
| Return on tangible assets | -72.0% | -112.7% | -119.7% | -121.7% | -74.2% | |
| Return on equity | 70.3% | 84.6% | 99.4% | 93.1% | 143.2% | |
| Return on invested capital | -56.9% | -102.6% | -80.2% | -118.7% | -82.1% | |
| Return on capital employed | -58.2% | -104.9% | -81.2% | 253.6% | -330.6% | |
| Earnings yield | -19.3% | -23.2% | -22.8% | -20.5% | -14.7% | |
| Free cash flow yield | -17.0% | -22.3% | -15.6% | -20.5% | -13.0% | |
| Capex / Op. cash flow | -1.3% | -1.8% | -8.3% | -23.2% | -12.2% | |
| Capex / Depreciation | 24.8% | 39.2% | 165.2% | 428.1% | 235.7% | |
| Capex / Sales | 3.4% | 46.7% | 4917.0% | 32567.5% | 3593.5% | |
| SG&A / Sales | 129.9% | 1144.7% | 20839.2% | 42795.0% | 14481.4% | |
| R&D / Sales | 183.5% | 1289.5% | 37357.9% | 103395.4% | 20980.5% | |
| Stock comp / Sales | 32.5% | 233.5% | 7904.0% | 16741.2% | 6122.2% | |
| Intangibles / Total assets | 2.8% | 4.2% | 3.4% | 5.5% | 0.3% | |
| Days sales outstanding | 137d | 66d | 1859d | 2874d | 521d | |
| Days payables outstanding | 3382d | 0d | 0d | 0d | 0d | |
| Operating cycle | 578d | 66d | 1859d | 2874d | 521d | |
| Cash conversion cycle | -2804d | 66d | 1859d | 2874d | 521d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-10-08 ImmunityBio to Participate in the Piper Sandler Virtual Oncology Symposium ImmunityBio, Inc. ([url="]NASDAQ: IBRX[/url]), a commercial-stage immunotherapy company, today announced that Dr. Patrick Soon-Shiong, its Founder, Executive Ch
- 2026-10-08 ImmunityBio to Participate in the Piper Sandler Virtual Oncology Symposium CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that Dr. Patrick Soon-Shiong, its Founder, Executive Chairman and Global Chief Scientific and Medical Officer, will participate virtually in a fireside chat at the Piper Sandler Virtual Oncology Symposium, taking place October 15-16, 2026. Details of the event are provided below: Piper Sandler Virtual Oncology Symposium – Fireside Chat Participant: Patrick Soon-Shion.
- 2026-10-08 ImmunityBio, Inc. (NASDAQ:IBRX) Receives Average Recommendation of “Moderate Buy” from Brokerages ImmunityBio, Inc. (NASDAQ: IBRX - Get Free Report) has earned an average rating of "Moderate Buy" from the seven analysts that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The
- 2026-10-02 ImmunityBio Stock Jumps: What''s Going On? ImmunityBio Inc. (NASDAQ:IBRX) shares are soaring Friday, extending a steadily rising pattern that''s played out over the past several months.
- 2026-09-24 State Street Corp Grows Holdings in ImmunityBio, Inc. $IBRX State Street Corp raised its position in ImmunityBio, Inc. (NASDAQ: IBRX) by 20.8% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 21,398,438 shares of the company''s stock after buying an additional 3,690,335 shares during the period. State Street
- 2026-09-18 ImmunityBio (IBRX) Moves 7.0% Higher: Will This Strength Last? ImmunityBio (IBRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- 2026-09-17 Tidal Investments LLC Acquires New Stake in ImmunityBio, Inc. $IBRX Tidal Investments LLC bought a new position in shares of ImmunityBio, Inc. (NASDAQ: IBRX) in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 252,048 shares of the company''s stock, valued at approximately $2,207,000. Several other hedge funds and other institutional investors have also
- 2026-09-16 ImmunityBio, Inc. (NASDAQ:IBRX) Receives $14.20 Consensus Target Price from Brokerages ImmunityBio, Inc. (NASDAQ: IBRX - Get Free Report) has been given a consensus rating of "Moderate Buy" by the seven research firms that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company. The average 1-year target
- 2026-09-03 Why Is ImmunityBio (IBRX) Up 9.7% Since Last Earnings Report? ImmunityBio (IBRX) reported earnings 30 days ago. What''s next for the stock?
- 2026-09-03 ImmunityBio: None Of The Moonshots Is Priced In ImmunityBio is rated a strong buy, driven by ANKTIVA''s FDA approval for BCG-unresponsive NMIBC and significant pipeline expansion potential. Current valuation reflects success in bladder cancer and BCG-naïve expansion, but assigns limited value to systemic immunotherapy potential in NSCLC or other types of cancer. Key near-term catalysts include phase 3 NSCLC data and BCG-naïve bladder cancer trial results, both of which could unlock substantial upside.